Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Oct;36(10):1251-1255.
doi: 10.1111/dme.13912. Epub 2019 Feb 15.

Association between HbA1c and the development of cystic fibrosis-related diabetes

M Choudhury  1   2 , P Taylor  3 , P H Morgan  4 , J Duckers  1 , D Lau  1 , L George  1 , R I Ketchell  1 , F S Wong  1   2
Affiliations

Association between HbA1c and the development of cystic fibrosis-related diabetes

M Choudhury et al. Diabet Med. 2019 Oct.

Abstract

Aims: To examine HbA1c as a predictor of risk for future development of cystic fibrosis-related diabetes and to assess the association with the development of retinopathy in people with cystic fibrosis-related diabetes.

Methods: A 7-year retrospective longitudinal study was conducted in 50 adults with cystic fibrosis, comparing oral glucose tolerance test results with HbA1c values in predicting the development of cystic fibrosis-related diabetes. Retinal screening data were also compared with HbA1c measurements to assess microvascular outcome.

Results: An HbA1c value ≥37 mmol/mol (5.5%; hazard ratio 3.49, CI 1.5-8.1) was significantly associated with the development of dysglycaemia, as defined by the oral glucose tolerance test over a 7-year period. Severity of diabetic retinopathy was associated with a higher HbA1c and longer duration of cystic fibrosis-related diabetes.

Conclusion: There is a link between HbA1c level and the future development of dysglycaemia in cystic fibrosis based on oral glucose tolerance test, as well as microvascular outcomes. Although current guidance does not advocate the use of HbA1c as a diagnostic tool in cystic fibrosis-related diabetes, it may be of clinical use in determining individuals at risk of future development of cystic fibrosis-related diabetes.

PubMed Disclaimer

References

    1. Milla CE, Warwick WJ, Moran A. Trends in Pulmonary Function in Patients with Cystic Fibrosis Correlate with the Degree of Glucose Intolerance at Baseline. Am J Respir Crit Care Med 2016; 162: 891-895.
    1. Hameed S, Morton JR, Jaffe A, Field PI, Belessis Y et al. Early glucose abnormalities in cystic fibrosis are preceeded by poor weight gain. Diabetes Care 2010; 33: 221-226.
    1. Courtney JM, Bradley J, Mccaughan J, O'Connor TM, Shortt C, Bredin CP, Bradbury I, Elborn JS. Predictors of mortality in adults with cystic fibrosis. Pediatr Pulmonol 2007; 42: 525-537.
    1. Bridges N, Rowe R, Holt RIG. Unique challenges of cystic fibrosis-related diabetes. Diabet Med 2018; 35: 1181-1188.
    1. UK Cystic Fibrosis Trust Diabetes Working Group. Management of Cystic Fibrosis related Diabetes Mellitus. Report of the UK Cystic Fibrosis Trusts Diabetes Working Group. 2nd floor, One Aldgate, London, 2004. Available at https://www.cysticfibrosis.org.uk/~/media/&/the-work-we&/cfrd-me.... Last accessed 8 May 2018.